SARS-CoV/SARS-CoV-2 Nucleocapsid Antibody, Rabbit MAb (40143-R001)
SARS-CoV/SARS-CoV-2 Nucleocapsid抗体, Rabbit MAb
用户验证的应用
经验证应用
| 项目 | 详情 |
|---|---|
| WB | 1:5000-1:20000 |
| ELISA | 1:5000-1:10000 |
| IHC-P | 1:5000-1:20000 |
| ICC-IF | 1:20-1:100 |
应用说明
(Antibody's applications have not been validated with corresponding viruses. Optimal concentrations/dilutions should be determined by the end user.)
推荐稀释说明
Optimal concentrations/dilutions should be determined by the end user.
详细信息
特异性
SARS-CoV Nucleocapsid Has cross-reactivity in ELISA and WB with SARS-CoV-2 Nucleocapsid Protein (Cat# 40588-V08B) Has cross-reactivity in ELISA with SARS-CoV-2 Omicron (B.1.1.529) Nucleocapsid Protein (Cat #40588-V07E34) SARS-CoV-2 Omicron (BA.2) Nucleocapsid Protein (Cat# 40588-V07E35) SARS-CoV-2 Omicron XE(BA.1 x BA.2) Nucleocapsid Protein (Cat# 40588-V07E36) SARS-CoV-2 Omicron (BA.4) Nucleocapsid Protein (Cat# 40588-V07E37) SARS-CoV-2 Delta (B.1.617) Nucleocapsid (D377Y) Protein (Cat# 40588-V07E16) SARS-CoV-2 Delta (B.1.617) Nucleocapsid (R203M, D377Y) Protein (Cat# 40588-V07E20) SARS-CoV-2 Delta (B.1.617.2) Nucleocapsid Protein (Cat# 40588-V07E29) SARS-CoV-2 Delta (B.1.617.3) Nucleocapsid (P67S, R203M, D377Y) Protein (Cat# 40588-V07E30) SARS-CoV-2 Alpha (B.1.1.7) Nucleocapsid(R203K, G204R) Protein (Cat# 40588-V07E1) SARS-CoV-2 Alpha (B.1.1.7) Nucleocapsid(I292T) Protein (Cat# 40588-V07E4) SARS-CoV-2 Alpha (B.1.1.7) Nucleocapsid(D3L, R203K, G204R, S235F) Protein (Cat# 40588-V07E7) SARS-CoV-2 Alpha (B.1.1.7) Nucleocapsid(D3L, S235F) Protein (Cat# 40588-V07E8) SARS-CoV-2 Alpha(B.1.1.7/ B.1.237) Nucleocapsid(S194L) Protein (Cat# 40588-V07E3) SARS-CoV-2 Alpha/beta(B.1.1.7/ B.1.351/ A.2.2) Nucleocapsid(P13L) Protein (Cat# 40588-V07E2) SARS-CoV-2 Beta(B.1.351/B.1.351.2/b.1.351.3/B.1.427/B.1.429) Nucleocapsid (T205I) Protein (Cat# 40588-V07E9) SARS-CoV-2 Gamma(P.1/ P.1.1/ P.1.2) Nucleocapsid (P80R) Protein (Cat# 40588-V07E11) SARS-CoV-2 Eta(B.1.525) Nucleocapsid (A12G, T205I) Protein (Cat# 40588-V07E19) SARS-CoV-2 Nucleocapsid Protein (Cat# 40588-V07E) No cross-reactivity in ELISA with MERS-CoV Nucleocapsid protein (Cat# 40068-V08B) HCoV-229E Nucleocapsid protein (Cat# 40640-V07E) HCoV-NL63 Nucleocapsid protein (Cat# 40641-V07E) HCoV-HKU1(isolate N5) Nucleocapsid protein (Cat# 40642-V07E) HCoV-OC43 Nucleocapsid protein (Cat# 40643-V07E)
制备方法
This product is a recombinant monoclonal antibody expressed from HEK293 cells.
运输条件
This antibody is shipped as liquid solution at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
背景信息
Coronaviruses are enveloped viruses with a positive-sense RNA genome and with a nucleocapsid of helical symmetry. Coronavirus nucleoproteins localize to the cytoplasm and the nucleolus, a subnuclear structure, in both virus-infected primary cells and in cells transfected with plasmids that express N protein. The coronavirus N protein is required for coronavirus RNA synthesis and has RNA chaperone activity that may be involved in template switch. Nucleocapsid protein is the most abundant protein of coronavirus. During virion assembly, N protein binds to viral RNA and leads to the formation of the helical nucleocapsid. Nucleocapsid protein is a highly immunogenic phosphoprotein also implicated in viral genome replication and in modulating cell signaling pathways. Because of the conservation of the N protein sequence and its strong immunogenicity, the N protein of coronavirus is chosen as a diagnostic tool. References 1.Van Boheemen S, et al. (2012), MBio. 3(6):e00473-12. Bisht H. et al., 2004, Proc Natl Acad Sci. 101 (17): 6641-6. Li W. et al., 2005, Science. 309 (5742): 1864-8.
文献引用 (129)
Unraveling microglial spatial organization in the developing human brain with DeepCellMap, a deep learning approach coupled with spatial statistics
使用 DeepCellMap(一种结合空间统计的深度学习方法)揭示发育中的人类大脑中的小胶质细胞空间组织
An mRNA vaccine encoding the SARS-CoV-2 Omicron XBB.1.5 receptor-binding domain protects mice from the JN.1 variant
编码SARS-CoV-2 Omicron XBB.1.5受体结合域的mRNA疫苗可保护小鼠免受JN.1变异株的感染。
Structure-guided engineering of a mutation-tolerant inhibitor peptide against variable SARS-CoV-2 spikes.
针对SARS-CoV-2变异刺突蛋白,通过结构导向工程设计一种耐突变抑制肽
Variant mutation G215C in SARS-CoV-2 nucleocapsid enhances viral infection via altered genomic encapsidation.
SARS-CoV-2 核衣壳中的变异突变 G215C 通过改变基因组包装增强病毒感染
ACE-2 blockade and TMPRSS2 inhibition mitigate SARS-CoV-2 severity following cigarette smoke exposure in airway epithelial cells in vitro.
ACE-2 阻断和 TMPRSS2 抑制可减轻体外气道上皮细胞暴露于香烟烟雾后 SARS-CoV-2 的严重程度
Comparative analysis of replication and immune evasion among SARS-CoV-2 subvariants BA.2.86, JN.1, KP.2, and KP.3.
对 SARS-CoV-2 亚型 BA.2.86、JN.1、KP.2 和 KP.3 的复制和免疫逃避进行比较分析
Direct interaction of HMGB1 with SARS-CoV-2 facilitates its infection via RAGE-dependent endocytosis
HMGB1与SARS-CoV-2的直接相互作用通过RAGE依赖性内吞作用促进其感染。
Convergent evolution of the G3BP1-binding motif in betacoronavirus nucleocapsid proteins.
β冠状病毒核衣壳蛋白中G3BP1结合基序的趋同进化
Systems serology-based comparison of humoral immune responses induced by liposome or aluminum hydroxide adjuvanted SARS-CoV-2 spike protein
基于系统血清学的脂质体或氢氧化铝佐剂SARS-CoV-2刺突蛋白诱导的体液免疫反应比较
Dose-dependent serological profiling of AdCLD-CoV19-1 vaccine in adults
AdCLD-CoV19-1疫苗在成人中的剂量依赖性血清学特征
- 1
- 2
- 3
- 4
- 5
- 6
- 13